Posted by Michael Wonder on 26 Mar 2020
FDA continues to support transparency and collaboration in drug approval process as the clinical data summary pilot concludes
26 March 2020 - As our society becomes more global, it has become increasingly clear that the U.S. FDA needs to take a more collaborative approach to our drug approval process.
Today, drugs that are approved by the FDA to be marketed in the United States are developed both in and out of the United States.
Of the 46,391 participants in the clinical trials that supported the 48 novel drugs approved by the FDA in 2019, 60% of the participants were located outside the U.S., showing the international nature of drug development.
